| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
University of Pittsburgh Cancer Institute and
Departments of Pathology and
Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; and
National Cancer Institute, Bethesda, MD 20892
Alterations in the p53 gene occur frequently and can lead to accumulation of p53 protein in squamous cell carcinomas of the head and neck (SCCHN). Since accumulation of p53 is associated with enhanced presentation of wild-type sequence (wt) p53 peptides to immune cells, the development of pan vaccines against SCCHN has focused on wt p53 epitopes. We used the HLA-A2.1-restricted wt p53264–272 epitope to generate CTL from circulating precursor T cells of HLA-A2.1+ healthy donors and patients with SCCHN. Autologous peptide-pulsed dendritic cells were used for in vitro sensitization. CTL specific for the wt p53264–272 peptide were generated from PBMC obtained from two of seven normal donors and three of seven patients with SCCHN. These CTL were HLA class I restricted and responded to T2 cells pulsed with p53264–272 peptide as well as HLA-A2-matched SCCHN cell lines naturally presenting the epitope. Paradoxically, none of the tumors in the three patients who generated CTL could adequately present the epitope; two had a wt p53 genotype and no p53 protein accumulation, while the third tumor expressed a point mutation (R to H) in codon 273 that prevents presentation of the p53264–272 epitope. In contrast, patients who did not generate CTL had tumors that accumulated altered p53 and potentially could present the p53264–272 epitope. These findings suggest that in vivo, CTL specific for the wt p53264–272 peptide might play a role in the elimination of tumor cells expressing this epitope and in immunoselection of epitope-loss tumor cells. Immunoselection of tumors that become resistant to anti-p53 immune responses has important implications for future p53-based vaccination strategies.
This article has been cited by other articles:
|
|
 |
|
  K. D. Pavelko, K. L. Heckman, M. J. Hansen, and L. R. Pease An Effective Vaccine Strategy Protective against Antigenically Distinct Tumor Variants Cancer Res., April 1, 2008; 68(7): 2471 - 2478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Visus, D. Ito, A. Amoscato, M. Maciejewska-Franczak, A. Abdelsalem, R. Dhir, D. M. Shin, V. S. Donnenberg, T. L. Whiteside, and A. B. DeLeo Identification of Human Aldehyde Dehydrogenase 1 Family Member A1 as a Novel CD8+ T-Cell Defined Tumor Antigen in Squamous Cell Carcinoma of the Head and Neck Cancer Res., November 1, 2007; 67(21): 10538 - 10545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ito, A. Albers, Y. X. Zhao, C. Visus, E. Appella, T. L. Whiteside, and A. B. DeLeo The Wild-Type Sequence (wt) p5325-35 Peptide Induces HLA-DR7 and HLA-DR11-Restricted CD4+ Th Cells Capable of Enhancing the Ex Vivo Expansion and Function of Anti-wt p53264-272 Peptide CD8+ T Cells J. Immunol., November 15, 2006; 177(10): 6795 - 6803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Prasad, K. J. Farrand, S. A. Matthews, J. H. Chang, R. S. McHugh, and F. Ronchese Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells J. Immunol., January 1, 2005; 174(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Graner, A. Likhacheva, J. Davis, A. Raymond, J. Brandenberger, A. Romanoski, S. Thompson, E. Akporiaye, and E. Katsanis Cargo from Tumor-Expressed Albumin Inhibits T-Cell Activation and Responses Cancer Res., November 1, 2004; 64(21): 8085 - 8092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sirianni, P. K. Ha, M. Oelke, J. Califano, W. Gooding, W. Westra, T. L. Whiteside, W. M. Koch, J. P. Schneck, A. DeLeo, et al. Effect of Human Papillomavirus-16 Infection on CD8+ T-Cell Recognition of a Wild-Type Sequence p53264-272 Peptide in Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., October 15, 2004; 10(20): 6929 - 6937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bae, J. A. Martinson, and H. G. Klingemann Heteroclitic CD33 Peptide With Enhanced Anti-Acute Myeloid Leukemic Immunogenicity Clin. Cancer Res., October 15, 2004; 10(20): 7043 - 7052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Kaufman, W. Wang, J. Manola, R. S. DiPaola, Y.-J. Ko, C. Sweeney, T. L. Whiteside, J. Schlom, G. Wilding, and L. M. Weiner Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group J. Clin. Oncol., June 1, 2004; 22(11): 2122 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Balz, K. Scheckenbach, K. Gotte, U. Bockmuhl, I. Petersen, and H. Bier Is the p53 Inactivation Frequency in Squamous Cell Carcinomas of the Head and Neck Underestimated? Analysis of p53 Exons 2-11 and Human Papillomavirus 16/18 E6 Transcripts in 123 Unselected Tumor Specimens Cancer Res., March 15, 2003; 63(6): 1188 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hoffmann, A. D. Donnenberg, S. D. Finkelstein, V. S. Donnenberg, U. Friebe-Hoffmann, E. N. Myers, E. Appella, A. B. DeLeo, and T. L. Whiteside Frequencies of Tetramer+ T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in the Circulation of Patients with Head and Neck Cancer Cancer Res., June 1, 2002; 62(12): 3521 - 3529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hoffmann, J. Muller-Berghaus, R. L. Ferris, J. T. Johnson, W. J. Storkus, and T. L. Whiteside Alterations in the Frequency of Dendritic Cell Subsets in the Peripheral Circulation of Patients with Squamous Cell Carcinomas of the Head and Neck Clin. Cancer Res., June 1, 2002; 8(6): 1787 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hoffmann, D. J. Loftus, K. Nakano, M. J. Maeurer, K. Chikamatsu, E. Appella, T. L. Whiteside, and A. B. DeLeo The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264-272 Epitope J. Immunol., February 1, 2002; 168(3): 1338 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler Tumor Cell Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines Cancer Res., September 1, 2001; 61(17): 6445 - 6450. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
